Browse medicines, page 4 of 9
Some records contain detailed evidence; others currently contain only basic identity and regulatory information. Reviewed conclusions appear only when they are available for a specific use and group of people.
Showing 181–240 of 526 records
Filgrastim-Laha (Filkri)
Protein medicineApproved in the United States (FDA)Expanded recordHemicellulase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordHemin (Panhematin)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
The amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after
Hepatitis B Virus Subtype Adw Hbsag Surface Protein Antigen (Recombivax Hb / Heplisav-B)
Protein medicineLaboratory or animal-stage researchExpanded recordHuman Papillomavirus Type 31 L1 Capsid Protein Antigen (Gardasil 9)
Protein medicineLaboratory or animal-stage researchExpanded recordHuman Rotavirus A Type G2p7 Strain Sc2 Live Antigen (Rotateq)
Protein medicineLaboratory or animal-stage researchExpanded recordHuman Thrombin (Thrombin Human)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Use with manual compression
Ibalizumab-Uiyk (Trogarzo)
Protein medicineApproved in the United States (FDA)Expanded recordIdursulfase (Elaprase)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Hunter syndrome
Imiglucerase (Cerezyme)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease
Infliximab-Abda (Renflexis)
Protein medicineApproved in the United States (FDA)Expanded recordInfliximab-Axxq (Avsola)
Protein medicineApproved in the United States (FDA)Expanded recordInfluenza A Virus A/Switzerland/6849/2025 Ivr-278 Antigen (Fluzone Tiv Sh 2026 / Fluzone Trivalent Northern Hemisphere / Fluzone / Fluzone High Dose Northern Hemisphere)
Protein medicineLaboratory or animal-stage researchExpanded recordInsulin Aspart Recombinant (Novolog / Novolog Penfill / Novolog Innolet)
Protein medicineApproved in the United States (FDA)Expanded recordInsulin Aspart-Xjhz (Kirsty)
Protein medicineApproved in the United States (FDA)Expanded recordInsulin Detemir Recombinant (Levemir / Levemir Innolet / Levemir Penfill)
Protein medicineApproved in the United States (FDA)Expanded recordInvertase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordJapanese Encephalitis Virus Strain Sa 14-14-2 Antigen (Ixiaro)
Protein medicineLaboratory or animal-stage researchExpanded recordLactoperoxidase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordLanadelumab-Flyo (Takhzyro)
Protein medicineApproved in the United States (FDA)Expanded recordLipase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordLonapegsomatropin (Skytrofa)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
SKYTROFA (lonapegsomatropin-tcgd) is a human growth hormone indicated for the: Treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH). Replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD). SKYTROFA is a human growth hormone indicated for: Pediatric Patients: Treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH) ( 1 ).
Luspatercept-Aamt (Reblozyl)
Protein medicineApproved in the United States (FDA)Expanded recordMalt Diastase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordMeasles Virus Strain Enders' Attenuated Edmonston Live Antigen (M-M-R II / Proquad)
Protein medicineLaboratory or animal-stage researchExpanded recordMucor Circinelloides F. Lusitanicus
Protein medicineLaboratory or animal-stage researchExpanded recordNattokinase (Jba Verestor Mega Fiber Caffe Latte / St. Paul Brands Verestor / Jba Verestor Mega Fiber Powder)
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordNeisseria Meningitidis Group Y Capsular Polysaccharide Tetanus Toxoid Conjugate Antigen (Menquadfi)
Protein medicineLaboratory or animal-stage researchExpanded recordPeptidase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordPyrethrum Extract (Pyrethrum)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Uses Uses treats head lice, pubic (crab) lice, and body lice
Somapacitan (Sogroya)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Pediatric patients aged 2
Streptococcus Pneumoniae Type 33f Capsular Polysaccharide Diphtheria Crm197 Protein Conjugate Antigen (Vaxneuvance / Capvaxive / Prevnar 20)
Protein medicineLaboratory or animal-stage researchExpanded recordAlbumin Iodinated I-125 Serum (Jeanatope)
Protein medicineApproved in the United States (FDA)Expanded recordAldesleukin (Proleukin / Guna-Il 2)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Metastatic renal cell carcinoma
Alglucosidase alfa (Lumizyme / Myozyme)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Pompe disease
Amivantamab and Hyaluronidase-Lpuj (Rybrevant Faspro)
Protein medicineApproved in the United States (FDA)Expanded recordAnsuvimab-Zykl (Ebanga)
Protein medicineApproved in the United States (FDA)Expanded recordAprotinin (Trasylol)
Protein medicineApproved in the United States (FDA)Expanded recordAsparaginase (Elspar / Rylaze)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma
Atacicept-Vymj (Trutakna)
Protein medicineApproved in the United States (FDA)Expanded recordAtezolizumab and Hyaluronidase-Tqjs (Tecentriq Hybreza)
Protein medicineApproved in the United States (FDA)Expanded recordAutologous Cultured Chondrocytes (Maci)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
The repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement
Avalglucosidase Alfa-Ngpt (Nexviazyme)
Protein medicineApproved in the United States (FDA)Expanded recordAxatilimab-Csfr (Niktimvo)
Protein medicineApproved in the United States (FDA)Expanded recordBacillus Anthracis Strain V770-Np1-R Antigens (Cyfendus / Biothrax)
Protein medicineLaboratory or animal-stage researchExpanded recordBecaplermin (Regranex / Regranex Gel 0.01%)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply, when used
Belantamab Mafodotin-Blmf (Blenrep)
Protein medicineApproved in the United States (FDA)Expanded recordBerahyaluronidase Alfa-Pmph (Keytruda)
Protein medicineApproved in the United States (FDA)Expanded recordBevacizumab-Adcd (Vegzelma)
Protein medicineApproved in the United States (FDA)Expanded recordBevacizumab-Bvzr (Zirabev)
Protein medicineApproved in the United States (FDA)Expanded recordBevacizumab-Maly (Alymsys)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. (1.1) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. (1.1) Limitations of Use: Alymsys is not indicated for adjuvant treatment of colon cancer.
Binetrakin (Guna-Il 4)
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordUse listed on the medicine record
DIRECTIONS Take 15 minutes before meals. Adults and children 12 years and older 20 drops twice a day in a little water. Hold in the mouth for about 30 seconds then swallow. Children between 12 years and 6 years of age 10 drops twice a day in a little water. Hold in the mouth for about 30 seconds then swallow. Children under 6 years consult a physician
Brentuximab Vedotin (Adcetris)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine ( 1.1 ). • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide ( 1.2 ).
Burosumab-Twza (Crysvita)
Protein medicineApproved in the United States (FDA)Expanded recordCalfactant (Infasurf Preservative Free / Infasurf)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
The risk of respiratory distress syndrome (RDS) in preterm neonates <29 weeks of gestational age at risk for RDS
Cemiplimab-Rwlc (Libtayo)
Protein medicineApproved in the United States (FDA)Expanded recordChymopapain (Chymodiactin)
Protein medicineApproved in the United States (FDA)Expanded recordCipaglucosidase alfa (Pombiliti Atga)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
POMBILITI is indicated, in combination with Opfolda, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT). POMBILITI is a hydrolytic lysosomal glycogen-specific enzyme indicated, in combination with Opfolda, an enzyme stabilizer, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT).
Collagenase Clostridium Histolyticum-Aaes (Qwo)
Protein medicineApproved in the United States (FDA)Expanded recordDaratumumab and Hyaluronidase-Fihj (Darzalex Faspro)
Protein medicineApproved in the United States (FDA)Expanded record